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Abstract: BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) is the most com-
mon monogenic inherited kidney disease, affecting an estimated 600 000 individuals in Europe. The
disease is characterized by age-dependent development of a multiple cysts in the kidneys, ultimately
leading to end-stage renal failure and the need of renal replacement therapy in the majority of patients,
typically by the fifth or sixth decade of life. The variable disease course, even within the same family,
remains largely unexplained. Similarly, assessing disease severity and prognosis in an individual with
ADPKD remains difficult. Epidemiological studies are limited due to the fragmentation of ADPKD re-
search in Europe. METHODS: The EuroCYST initiative aims: (i) to harmonize and develop common
standards for ADPKD research by starting a collaborative effort to build a network of ADPKD reference
centres across Europe and (ii) to establish a multicentric observational cohort of ADPKD patients. This
cohort will be used to study factors influencing the rate of disease progression, disease modifiers, disease
stage-specific morbidity and mortality, health economic issues and to identify predictive disease progres-
sion markers. Overall, 1100 patients will be enrolled in 14 study sites across Europe. Patients will be
prospectively followed for at least 3 years. Eligible patients will not have participated in a pharmaceutical
clinical trial 1 year before enrollment, have clinically proven ADPKD, an estimated glomerular filtration
rate (eGFR) of 30 mL/min/1.73 m(2) and above, and be able to provide written informed consent. The
baseline visit will include a physical examination and collection of blood, urine and DNA for biomarker
and genetic studies. In addition, all participants will be asked to complete questionnaires detailing self-
reported health status, quality of life, socioeconomic status, health-care use and reproductive planning.
All subjects will undergo annual follow-up. A magnetic resonance imaging (MRI) scan will be carried
out at baseline, and patients are encouraged to undergo a second MRI at 3-year follow-up for qualitative
and quantitative kidney and liver assessments. CONCLUSIONS: The ADPKD reference centre network
across Europe and the observational cohort study will enable European ADPKD researchers to gain in-
sights into the natural history, heterogeneity and associated complications of the disease as well as how
it affects the lives of patients across Europe.
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1 Summary: The EuroCYST Initiative aims to build a network of ADPKD reference centers 
2 
3 
across Europe and to establish a large-scale observational cohort of ADPKD patients for the 
4 
5 
6 purpose of studying the pathogenesis, rate of disease progression, progression rate modifiers, 
7 
8 disease stage specific morbidity, mortality, health economic issues and the predictive value of 
9 
10 biomarkers in ADPKD. Overall 1,100 patients will be enrolled in 14 study sites across Europe 
11 
12 and will be followed up for at least three years. The ADPKD reference center network across 
13 
14 
Europe and the observational cohort study will enable European ADPKD researchers to gain 
 
16 
17 insight into the natural history, heterogeneity and associated complications of the disease as 
18 
19 well as how it affects the lives of patients across Europe. 
20 
21 
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30 ml/min/1.73m
2  
and above and be able to provide written informed consent. The baseline 
visit  will  include  a  physical  examination  and  collection  of  blood,  urine  and  DNA  for 
biomarker  and  genetic  studies.  In  addition,  all  participants  will  be  asked  to  complete 
questionnaires  detailing  self-reported  health  status,  quality  of  life,  socioeconomic  status, 
healthcare  use  and  reproductive  planning.  All  subjects  will  undergo  annual  follow-up.  A 
magnetic  resonance  imaging  (MRI)  scan  will  be  carried  out  at  baseline  and  patients  are 
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1 
2 
3 
Abstract 
4 
5 
6 
7 
8 Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most common 
9 
10 monogenic inherited kidney disease, affecting an estimated 600,000 individuals  in Europe. 
11 
12 The disease is characterized  by age dependent development  of a multitude  of cysts in the 
13 
14 
kidneys,  ultimately  leading  to  end-stage  renal  failure  and  the  need  of  renal  replacement 
 
16 
17 therapy in the majority of patients,  typically by the 5
th  or 6th  decade of life. The variable 
18 
19 disease course, even within the same family, remains largely unexplained. Similarly, assessing 
20 
21 disease severity and prognosis in an individual with ADPKD remains difficult. Epidemiologic 
22 
23 
studies are limited due to the fragmentation of ADPKD research in Europe. 
24 
25 
26 
27 Methods: The EuroCYST Initiative aims (i) to harmonize and develop common standards for 
28 
29 ADPKD research by starting a collaborative effort to build a network of ADPKD reference 
30 
31 centers across Europe; and (ii) to establish a multicentric  observational  cohort of ADPKD 
32 
33 patients. This cohort will be used to study factors influencing the rate of disease progression, 
34 
35 
disease modifiers, disease stage specific morbidity and mortality, health economic issues and 
36 
37 
38 to identify predictive disease progression markers. Overall 1,100 patients will be enrolled in 
39 
40 14 study sites across Europe. Patients will be followed prospectively for at least three years. 
41 
42 Eligible patients will not have participated in a pharmaceutical clinical trial one year before 
43 
44 
enrollment, have clinical proven ADPKD, an estimated glomerular filtration rate (eGFR) of 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
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1 encouraged  to undergo a second MRI at 3 years follow-up for qualitative  and quantitative 
2 
3 
kidney and liver assessments. 
4 
5 
6 
7 Conclusion: The ADPKD  reference  center  network  across  Europe  and  the  observational 
8 
9 cohort study will enable European ADPKD researchers to gain insight into the natural history, 
10 
11 heterogeneity and associated complications of the disease as well as how it affects the lives of 
12 
13 patients across Europe. 
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At present there are no approved disease modifying treatments available for ADPKD. 
Intensive   basic   research   during   the   last   three   decades   has   contributed   to  a  clearer 
understanding of the basic pathophysiological  processes that lead to renal cyst formation in 
subjects affected by ADPKD with definition of novel therapeutic targets.
5,6  
In animal studies 
some  of the treatments  directed  at these  targets,  such as mammalian  target  of rapamycin 
(mTOR) inhibitors, somatostatin analogues and vasopressin V2-receptor antagonists (V2RA), 
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1 
2 Introduction 
3 
4 
5 
6 Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common 
7 
8 
monogenic  genetic  diseases,  affecting  approximately  1  in  1,000  live  births,  i.e.  around 
10 
11 600,000 individuals in Europe.
1  The disease is characterized by the development of multiple 
12 
13 cysts  in  both  kidneys  and  by  potentially  serious  complications.
2   
Disease  manifestations 
14 
15 impairing   quality   of   life   include   hypertension,   chronic   pain,   intracranial   aneurysms, 
16 
17 
abdominal hernias, hematuria, urinary tract infection, and kidney stones. Kidney function is 
18 
19 
20 often  preserved  up  to  the  age  of  40,  but  subsequently  glomerular  filtration  rate  (GFR) 
21 
22 decreases  and  often  leading  to  end-stage  renal  disease  (ESRD).
3   
However  there  is  wide 
23 
24 variability  between  subjects  in  disease  course,  even  within  families  that  share  the  same 
25 
26 
mutation, with some patients never reaching ESRD. 
27 
28 
29 
30 ADPKD  represents  a major  burden  for public  health  in the EU, estimated  at €1.6 
31 
32 
billion annually for direct medical costs related to renal replacement therapy.
4  
This figure is 
33 
34 
35 an underestimate  of the true economic burden, because it does not take into account costs 
36 
37 related to co-morbidities  which frequently occur in patients with impaired kidney function 
38 
39 and the loss of income generation that is often observed in subjects with later stage kidney 
40 
41 disease.  Research  on  prevention  of ADPKD  related  complications  could  therefore  offer a 
42 
43 
tremendous return on investment. 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
already reliably detect changes in total kidney volume that occur during 6 months of follow- 
up.
19 
However, the two interventional trials with mTOR inhibitors (references 10 and 11) did 
not observe a correlation between total renal volume and disease progression (as measured by 
renal function) questioning whether total kidney volume is a suitable surrogate marker for 
disease progression.  In addition,  this imaging technique is not routine clinical practice for 
ADPKD subjects in all European countries. Thus, there is a need to discover clinical factors 
or new biomarkers that predict the rate of disease progression. 
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1 have shown promising results.7-9  The clinical trials testing mTOR inhibitors showed no clear 
2 
3 
impact  on  disease  progression.
10-12    
However  recent  results  from  the  TEMPO  3:4  and 
4 
5 
6 ALADIN  trials  with  the V2RA Tolvaptan  and the  somatostatin  analogue  Octreotide  have 
7 
8 shown an effect on the rates of kidney growth and kidney function decline, although long 
9 
10 term  treatment  safety  needs  to  be  addressed.
13,14   
If  these  therapies  become  available  for 
11 
12 clinical  use,  the  pivotal  question  will  be which  patients  to select  for  treatment.  One  can 
13 
14 
hypothesize that ADPKD patients with rapid disease progression would benefit most and that 
 
16 
17 treatment should be started at an early stage of disease, when the kidneys are more likely to 
18 
19 respond to an intervention. Since ADPKD is characterized by a long period of stable kidney 
20 
21 function,  due to compensatory  filtration  of unaffected  nephrons,  kidney  function  does not 
22 
23 
accurately  reflect disease  severity  nor prognosis.
15   
Genotype  (PKD1 as opposed  to PKD2 
24 
25 
26 mutation), male gender and young age at onset of hypertension among others associate with 
27 
28 faster disease progression in ADPKD.
16,17  
However, the predictive value of these variables is 
29 
30 limited and untested in large prospective cohorts. The identification of surrogate markers to 
31 
32 assess disease severity and risk of progression and to monitor the effect of interventions on 
33 
34 
the course of disease remains an important goal and is an unmet medical need. Results of 
36 
37 smaller observational studies in ADPKD cohorts, like CRISP and SUISSE ADPKD, suggest 
38 
39 that changes in total kidney volume are a predictor of subsequent loss of kidney function.
18
 
40 
41 MRI has a greater sensitivity for the detection of small cysts and allows to measure kidney 
42 
43 
and liver volume more precisely compared to ultrasound. It has been shown that MRI can 
44 
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1 Building a large, well-characterized cohort of ADPKD subjects who are followed in a 
2 
3 
longitudinal observational cohort study has the potential to identify progression factors and 
4 
5 
6 biomarkers,  and to assess disease stage specific mortality, morbidity and health care costs. 
7 
8 This  knowledge  should  translate  into  new  diagnostic  and  therapeutic  modalities.  This 
9 
10 approach requires a coordinated multinational action within a network of ADPKD reference 
11 
12 centers. The EuroCYST Initiative aims to build such a network and to establish a large-scale 
13 
14 
pan-European ADPKD cohort serving as a versatile and powerful clinical research platform. 
 
16 
17 Since EuroCYST is an academic initiative and not industry driven, free access to information 
18 
19 and  pseudo-anonymized   biomaterial   is  ensured,  as  approved   by  a  research   oversight 
20 
21 committee. 
22 
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collaborative  and  educational  liaisons  as  well  as  provide  standard  criteria  for  effective 
management protocols in ADPKD. 
• Improve awareness of the relevance of   ADPKD including disease-specific 
complications   and   socioeconomic   consequences   of   the   disease   among   health   care 
professionals and payers. 
9 of 27 
 
 
 
 
 
1 
2 
3 Methods 
4 
5 
6 
Objectives 
7 
8 
9 The primary objectives of the EuroCYST Initiative are to: 
10 
11 
12 
13 • Build a network of ADPKD reference centers across Europe to provide a translational 
14 
15 research  platform  that  will  enable  EU  researchers  to  study  the  pathogenesis,  progression 
16 
17 
factors, morbidity, co-morbidity and health economic issues in ADPKD patients over a wide 
18 
19 
20 range of kidney function and kidney volume. 
21 
22 • Harmonize  and  develop  common  standards  for  ADPKD  related  research  by  a 
23 
24 collaborative effort to establish a pan-European ADPKD cohort. 
25 
26 
• Harmonize  and  develop  a  common  ADPKD  biobank  that  includes  standardized, 
27 
28 
29 quality-controlled biomaterials for translational research. 
30 
31 • Create a scaffold to facilitate the integration of current and upcoming technologies to 
32 
33 ADPKD practice. 
34 
35 
• Develop evidence-based best practice and needs assessments for ADPKD by utilizing 
36 
37 
38 the  outcomes  of  the  EuroCYST  Initiative  and  by  engaging  with  relevant  stakeholders, 
39 
40 including patient organizations, clinical and research networks, legislators, policymakers and 
41 
42 the pharmaceutical industry. 
43 
44 
• Serve as an impetus to expand ADPKD training programs at all levels by establishing 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
with  other  research  groups  to  share  data  and  biomaterials  in order  to achieve  maximum 
scientific  output  will be encouraged.  To this end an  open and transparent  ancillary  study 
policy has been established as part of the study protocol (Supplement S1). 
A Steering Committee has been established and is meeting at least twice a year. All 
decisions by the Steering Committee will be approved on a 75% majority. The establishment 
10 of 27 
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1 EuroCYST strategy and organization 
2 
3 
4 To build a cohort for a longitudinal  observational  study, 14 centers in 10 countries 
5 
6 across Europe (Figure 1) will enroll 1,100 adult ADPKD patients until the end of 2015. The 
7 
8 study is funded by a grant of the ERA-EDTA with 1 Million Euros.  For optimal utilization of 
9 
10 
the funding, centers with expertise in ADPKD and already existing local clinical cohorts have 
12 
13 been co-opted, so that efforts do not need to focus on recruitment, but can be invested into the 
14 
15 establishment  of the cohort infrastructure,  uniform data recording and in depth analysis of 
16 
17 several time and thus resource-consuming  aspects, such as assisted patient interviews using 
18 
19 
standardized questionnaires. 
20 
21 
22 
23 The  enrollment  phase  started  in  summer  2013;  within  one  year,  250  participants 
24 
25 
should  be included.  In order to reach the goal of recruiting  1,100 ADPKD  patients,  each 
27 
28 participating ADPKD  center will enroll at least 50 and up to a maximum  of 100 patients 
29 
30 within two years to ensure a representative distribution of patients across Europe. In a second 
31 
32 step, which is beyond the current funding period, the cohort could be extended in four ways: 
33 
34 
a) prolong  the  intended  duration  of follow-up  to longer  than three  years,  b) increase  the 
35 
36 
37 number of patients up to 5,000 or more through the participation of additional European study 
38 
39 centers with a minimum essential dataset, c) increase the information density per patient for 
40 
41 specific  aspects  (e.g.  cardio-vascular  pathology,  imaging,  genetics),  or d)  enroll  partners, 
42 
43 children and parents of index patients (3-generation cohort). The participation of additional 
44 
45 
centers will be possible if appropriate funding is obtained. Collaborations  at various levels 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
Patients who meet the inclusion  criteria will be invited to participate. All potential 
participants  will receive detailed information about the study both verbally and in writing. 
Local  ethical  committees  will  approve  the  study  and the protocol  has to fulfill  the local 
regulatory requirements and complies with Good Clinical Practice Guidelines (GCP). 
The study design is shown in Figure 2. At baseline a detailed medical and ADPKD- 
specific assessment will be performed. Family history/pedigree information will be collected, 
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29 
38 
 
 
 
1 of a Central Study Coordination Team, which meets on a bi-weekly basis, will ensure rapid 
2 
3 
and successful project implementation and progress. 
4 
5 
6 
7 
8 
9 
10 Eligibility  of cohort participants 
11 
12 
13 Following a consecutive enrollment approach all patients with ADPKD are considered 
14 
15 as potentially eligible for the study at pre-screening and will undergo screening for the study. 
16 
17 
Patients aged 18 years and older with an estimated GFR (eGFR) of 30 ml/min/1.73m
2  
and 
18 
19 
20 higher  (CKD-EPI  formula),  having  a  diagnosis  of ADPKD  established  based  on  kidney 
21 
22 ultrasound and family history (modified Ravine criteria) who have not taken part in a disease 
23 
24 modifying trial at least one year or shorter before enrollment and are able to provide written 
25 
26 informed  consent  will  be  eligible  for  enrollment  into  the  EuroCYST  cohort.
20,21   
Table  1 
27 
28 
displays  the  inclusion  and  exclusion  criteria.  Exclusion  criteria  include  the  likelihood  of 
30 
31 reaching ESRD within one year after enrollment or significant heart disease according to New 
32 
33 York  Heart Association  stage  IV (NYHA  stage  IV).
22    
A stratification  strategy  based  on 
34 
35 
subjects eGFR will avoid selection bias. Each study center will enroll 40 to 60% of patients 
36 
37 
with eGFR greater or equal and under 60 ml/min*1.73m
2 
respectively. 
39 
40 
41 
42 
43 
44 Study design 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
saturation,  FISP  or FIESTA  3D spoiled  gradient  echo,  and T1-3D  spoiled  gradient  echo. 
Images  will  be  sent  using  Picture Archiving  and  Communication  System  (PACS)  to  the 
centers Zurich and Bergamo, where a read out by trained personnel will be performed. Read 
out of the scans includes whole kidney and cyst volume, length, depth, width of the kidney, 
numbers of cysts, and also liver and liver cyst volume, using the workstation GE Advantage 
and the program volume viewer. 
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1 as  well  as  information  on  medical  resource  use  (health  care  visits,  hospital  admission, 
2 
3 
procedures,  and  medication),  productivity  (employment,  absenteeism),  information  culture 
4 
5 
6 within  families  and  reproductive  planning.  The  economic  and  social  position,  based  on 
7 
8 income,  education,  and occupation  will  be assessed.  Quality  of life will  be  measured  by 
9 
10 asking  patients  to  complete  the  KDQOL-SF  1.2™  questionnaire,  that  includes  questions 
11 
12 relating  to patients  general  health,  kidney  disease  and about  the effect  of the  disease  on 
13 
14 
activities of daily living. The protocol will also require a physical examination. 
 
16 
17 
18 Follow-up  visits  will  be  conducted  on  an  annual  basis  until  the  end  of  study, 
19 
20 withdrawal, ESRD or death. Follow-up visits will include physical examination; laboratory 
21 
22 analyses   as   well   as   completing   the   aforementioned   ADPKD   related   questionnaires. 
23 
24 
Participating patients will be treated according to current standards of care in routine clinical 
25 
26 
27 practice within each country. 
28 
29 
30 
31 
32 
33 Magnetic  resonance imaging 
34 
35 
36 MRI  will  be  used  to measure  the  different  magnitudes  and  volume  parameters  of 
37 
38 
kidney and liver. MRI will be performed at the baseline visit and is recommended at 3-year 
39 
40 
41 follow-up. In order to obtain high quality renal and hepatic imaging and maintain consistency 
42 
43 between the centers participating in the trial, a standardized protocol has been developed. The 
44 
45 MRI  acquisition  protocol  includes  T2  single  shot  fast/turbo  spin  echo  images  with  fat- 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
a daily back up will be performed.  The study  data are saved  on a separate  server  at the 
University Hospital Zurich, where the clinical trial center, provider of the data management 
system, is located. Server access is controlled physically and electronically. Each patient will 
be  pseudo-anonymized   in  a  reversible  manner  and  all  data  introduced   into  the  data 
management system is coded. Subject identification will only be possible at the local study 
site. Access to the system will be role specific and will only be possible with a unique User- 
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1 Collection and storage of biological material 
2 
3 
4 
The collection of material for biobanking  will be conducted at the baseline visit. A 
5 
6 
7 Standard Operating Procedure (SOP) harmonizes the procedure for sampling, pre-processing 
8 
9 and storage of biobanking material within the EuroCYST Initiative. Serum, plasma and whole 
10 
11 blood collected on EDTA and spot and 24 h urines will be collected, processed and aliquoted. 
12 
13 They will be shipped in batches to a central biobank storage facility where an automated - 
14 
15 
80°C sample library management system is in place to handle the de-identified 2D bar coded 
16 
17 
18 sample vials. The whole blood tubes will be shipped to a central, certified genetic laboratory 
19 
20 for DNA extraction and storage. The database will be kept separately with a secure method to 
21 
22 link clinical information to biological samples. 
23 
24 
25 
26 
27 
28 
Data management and protection 
30 
31 
32 Data collection  and data management  will be conducted  using the web-based  data 
33 
34 management  system SecuTrial®,  with a data capture, which has been approved by the US 
35 
36 Food and Drug Administration (FDA) and that fulfills the requirements of the International 
37 
38 
Conference  on Harmonization  Good Clinical Practice (ICH GCP) and Good Clinical Data 
39 
40 
41 Management  Practices  (GCDMP).  All  electronic  case  report  forms  (eCRF)  have  been 
42 
43 implemented into this system. Figure 3 shows the different subject areas of the data bank that 
44 
45 are reflected in the eCRF. Data will be stored for at least 10 years after study termination and 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
disease progression  rate as assessed by the change  in eGFR rate and total kidney volume 
(TKV) despite restrictive inclusion and exclusion criteria. Therefore a larger sample size is 
required to account for the broader range in age and renal function in our cohort. A mixed 
effects regression model will be used as the modeling framework, with a random effect for 
each patient (this allows correlation  between repeated eGFR or TKV measurements  in the 
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1 ID and password. High data quality will be ensured by performing regular monitoring and 
2 
3 
reporting of entered data by the coordination center Zurich. All study site data entered in the 
4 
5 
6 eCRF will be checked for completeness and plausibility according to predefined rules to draw 
7 
8 attention to missing data or errors. Certified personnel will monitor the participating center 
9 
10 annually. All patients’ written informed consent forms and all study files will be checked for 
11 
12 completeness,  and remain  at the individual  sites.  In 10% of locally  enrolled  patients,  the 
13 
14 
source files and eCRFs will be checked for accuracy. In addition, frequent communications 
 
16 
17 and annual meetings of reference center principal investigators will ensure study compliance. 
18 
19 The center’s individual results of the study shall be owned by the center. Each center will 
20 
21 provide  copies  of all results,  including  but not limited  to case report forms,  to the study 
22 
23 
coordination center in Zurich. Owner of the overall data of the Initiative is the EuroCYST 
24 
25 
26 steering committee. 
27 
28 
29 
30 
31 
32 Statistical considerations 
33 
34 
35 Formal sample size estimation has not been performed for this study. While chronic 
36 
37 
kidney disease cohorts currently aim to enroll at least 3,000 and up to 5,000 patients (CRIC, 
38 
39 
40 CKD JAC, GCKD) to identify valid associations in subgroups, the common genetic origin in 
41 
42 APDKD allows important conclusions to be drawn using a smaller sample size.
23-25  
On the 
43 
44 other hand, groups of several hundred patients enrolled in recent randomized controlled trials 
45 
46 (RCTs) as well as already existing ADPKD cohorts have displayed large variability in the 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
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1 same  patient)  and with  fixed  effects  for time  with a spline  structure  to model  change  in 
2 
3 
estimated GFR and TKV. 
4 
5 
6 
7 
8 
9 
10 Study outcomes 
11 
12 
13 The primary outcome measure of the study will be disease progression, assessed as 
14 
15 change in eGFR (CKD-EPI) and change in TKV. Secondary outcome measure will be: firstly, 
16 
17 
onset and severity of ADPKD-related clinical outcomes, such as hypertension, albuminuria, 
18 
19 
20 renal  urine  concentrating  ability,  hematuria,  renal  pain,  cyst  infection  and  nephrolithiasis; 
21 
22 secondly, self-reported health status, quality of life and pain; thirdly, health related resource 
23 
24 use and ADPKD-related health burden. 
25 
26 
27 
28 
29 
30 
Enrollment Start 
31 
32 
33 
34 The study started enrolling patients in July 2013 and will run for 36 months. 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
EDTA Working Group on Inherited Kidney Disorders demonstrates the interest and need for a 
consolidated pan-European approach in the field of inherited kidney diseases at large.
30
 
The establishment of such a cohort has the potential to strengthen European ADPKD 
investigators  by  harmonizing  and  standardizing  research  efforts  and  will  guarantee  that 
current and upcoming technologies to study chronic kidney disease can be applied to ADPKD 
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1 Conclusion 
2 
3 
4 
5 The fragmentation of cohorts of ADPKD patients in Europe has been an obstacle to a 
6 
7 better understanding of disease characteristics. Individual efforts in different countries often 
8 
9 have  little inter-changeability  and it can be almost impossible  to connect  detailed clinical 
10 
11 
information held in one database with genetic information or biomaterial sample availability 
12 
13 
14 held in other databases. Our increasing knowledge of the basic biology of ADPKD has led to 
15 
16 the identification of multiple novel targets in pre-clinical studies, which will need to be tested 
17 
18 in patients. Positive results from recent clinical trials also now compel nephrologists to find 
19 
20 new ways of risk stratification to identify patients at higher risk of disease progression and 
21 
22 
who may benefit most from early intervention.  So far, limited data is available addressing 
 
24 
25 patients’  quality  of  life,  disease  related  health  burden,  health  care  resource  use  and 
26 
27 reproductive planning. Currently available data regarding quality of life for ADPKD patients 
28 
29 is limited and often only applicable to those on dialysis or transplanted patients.26-29 
30 
31 
32 
33 These  issues  motivated  the  EuroCYST  Initiative,  which  aims  to build  an ADPKD 
34 
35 reference center network in Europe in order to establish a large pan-European observational 
36 
37 
cohort  that  will  serve  as  a  scaffold  and  platform  enabling  researchers   to  study  the 
38 
39 
40 pathogenesis, progression factors, mortality, co-morbidity, as well as health economic issues 
41 
42 relevant to ADPKD as a major cause of kidney disease. Although there is an interest of the 
43 
44 pharmaceutical  industry to establish ADPKD  databases,  an independent  academic network 
45 
46 with a transparent open access policy remains essential. The recent establishment of the ERA- 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
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1 patients across Europe. Affected patients and their relatives will benefit from the scientific- 
2 
3 
medical  innovations  by improved  prevention  and awareness,  treatment  of disease-specific 
4 
5 
6 complications and development of new diagnostic and therapeutic modalities. 
7 
8 
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1 
2 
3 Tables 
4 
5 Table 1. In- and exclusion criteria for the EuroCYST observational cohort study. 
6 
7 
8 
9 Inclusion criteria 
10 • Age ≥ 18 
11 
• eGFR ≥ 30 ml/min/1.73m
2  
(CKD-EPI formula) 
 
13 • Clinical diagnosis  of ADPKD  based on kidney imaging and family 
14 
history (modified Ravine criteria) 
15 
16 • Patient provided written informed consent 
7 Exclusion criteria 
18 
19 • Receiving   chronic   renal   replacement   therapy   before   enrollment 
20 (dialysis, allograft) or anticipated to receive such therapy within 12 
21 
months after enrollment 
22 
23 • Participation in a clinical trial aiming to modify disease outcome one 
24 year or less before enrollment in the EuroCYST study 
25 
26 • NYHA stadium IV 
27 Abbreviations:  eGFR  –  estimated  glomerular  filtration  rate,  NYHA  –  New  York  Heart 
28 
29 Association 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
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52 
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54 
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1 
2 
3 Manuscript: Building a network of ADPKD Reference Centers across Europe: The 
4 EuroCYST Initiative (NDT-00126-2014) 
5 
6 
7 
8 Point by point answers to review NDT (February 4th, 2014) 
9 
10 
1. This cohort study  risks to induce a substantial selection bias towards “more serious disease”, 
11 
12 first because  only patients with advanced disease  will be identified (because  of symptoms), and 
13 not those with asymptomatic disease,  and second because  it can be imagined that only those 
14 with more advanced disease  will be motivated to participate. This aspect  is completely 
15 neglected in the paper, and should be discussed. 
16 We agree with reviewers’ comment that there might be a risk of enrolling a majority of patients with 
17 more advanced disease. In the EuroCYST study we recruit patient from a hospital setting. The cohort 
18 should reflect the range of outpatient cases. In the EuroCYST study, we might induce a study limitation 
19 because of a selection bias, in our case particularly a sampling bias. With choosing the hospital setting, 
20 
we might risk to enroll a majority of patients with advanced disease progression. This limitation could 
21 
lead to an over-representation of more patients with serious disease. For reducing the risk of a sampling 
23 bias, we propose the following approach: A stratification per study center of 40 to 60% of enrolled 
24 patients with eGFR greater or equal than 60 ml/min*1.73m2. 
25 
26 1.1 In the same line of reasoning the percentages of patients ending up on RRT is not really 
27 known, is as suggested in line 24 pg 7 
28 We adapted the paragraph as follows: “Kidney function is often preserved up to the age of 40, but 
29 subsequently glomerular filtration rate (GFR) decreases, and often leading to end-stage renal disease 
30 
(ESRD) between the 4th and 7th decade of life.3” 
31 
32 
33 2. Line 4-6 page 8: the results of the TEMPO trial are being presented here as “promising”; 
34 however, to my knowledge, the impact on effect size was minimal, and there was serious 
35 concern on hepatotoxicity of the drug.  Most nephrologists would not consider the result  of this 
36 study  as “promising”. This statement should be at least made more balanced, or be removed. 
37 We agree to reviewers’ opinion and modified the paragraph to “…The clinical trials testing mTOR 
38 inhibitors showed no clear impact on disease progression.10-12  However recent results from the TEMPO 
39 3:4 and ALADIN trials with the V2RA Tolvaptan and the somatostatin analogue Octreotide have shown 
40 
an effect on the rates of kidney growth and kidney function decline, despite the fact the that safety 
41 
issues of a long term treatment need to be addressed.13,14  …” 
43 
44 3. Line 38-39 page 8: again, the enthusiasm about changes in kidney size in relation to 
45 progression is a bit exaggerated; associations with renal function and evolution to RRT are in 
46 fact weak, especially in the lower, non caricatural range of kidney volume. There is at least much 
47 debate on the real value of kidney volume as surrogate marker.  This paragraph should be made 
48 more balanced. 
49 In response to the reviewers’ opinion we modified the paragraph into “…Results of smaller 
50 
observational studies in ADPKD cohorts, like CRISP and SUISSE ADPKD, suggest that changes in total 
51 
kidney volume are a predictor of subsequent loss of kidney function.18…” 
53 
54 4. Line 17-21 of page 9: it is stated that the group  acts independent from industry; however, the 
55 majority of authors of this paper clearly have ties with industry, and have participated in an 
56 industry sponsored RCT on this topic,  and many of them probably receive industry money  for 
57 their research; it is therefore strange that only one conflict of interest is declared. This is not 
58 really credible. 
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3 The present research project is academic, independent of industry and solely funded by the ERA-EDTA. 
4 All authors declare no conflict of interest. The COI form of the lead author will be submitted. 
5 
6 4.1 In the same line: it is stated that 14 centres will participate: how were these centres 
7 selected? 
8 
Centers with expertise in ADPKD research have been selected, so that efforts do not need to focus on 
9 
recruitment, but can be invested into the establishment of the cohort infrastructure, uniform data 
11 recording and time- and thus resource-consuming aspects, such as assisted patient interviews using 
12 standardized questionnaires. 
13 
14 4.2 Who made this selection? 
15 The selection of the participating center was made by the Steering Committee of the EuroCYST 
16 Initiative. 
17 The members of the Steering Committee are: 
18 
Prof. Dr. Olivier Devuyst (University Zurich) 
19 
Prof. Dr. Kai-Uwe Eckardt (University Hospital Erlangen) 
21 Dr. Ron Gansevoort (University Medical Center Groningen) 
22 Prof. Dr. Albert Ong (University of Sheffield) 
23 Prof. Dr Yves Pirson (Clinique universitaire Saint Luc Brussel) 
24 Prof. Dr. Giuseppe Remuzzi (IRCCS – Instituto di Ricerche Farmacologiche Mario Negri 
25 Bergamo) 
26 Prof. Dr. Richard Sandford (University of Cambridge) 
27 PD Dr. Andreas Serra (University Hospital Zurich) 
28 
Prof. Dr. Gerd Walz (University Hospital Freiburg) 
29 
30 
31 4.3 Is there any evidence to support that these centres are representative of “regular centres” 
32 and that their patients are representative of “regular“ patients? 
33 The centers that participate in this initiative are not regular centers, but centers with expertise in ADPKD 
34 research. We have changed the text of the manuscript to reflect this consideration. As the reviewer will 
35 know the rate of disease progression in ADPKD is characterized by a wide variability, even between 
36 pedigrees that share the same mutation in either of the PKD genes. So far it is therefore not possible to 
37 describe the “regular” ADPKD patient. The EuroCYST Initiative, pursuing a multinational approach, aims 
38 to address this issue. 
39 
40 
41 5. Recruitment process: how will this be done? 
42 Since all participating center have already established local cohorts with systematic data available, the 
43 recruitment of patients is arranged. 
44 
45 5.1 Is there any regulation to assure  consecutive rather than selective enrollment of ADPKD 
46 patients? 
47 We propose consecutive enrollment of study subjects. Consecutive enrollment is a measure to prevent 
48 selection bias and we think that consecutive enrollment is important since observational studies are 
49 
always compromised for selection bias that subsequently can’t be addressed by any statistical 
50 
51 approaches. Following a consecutive enrollment approach means that all ADPKD patients are 
52 considered as potentially eligible for the study at pre-screening and will undergo screening for 
53 EuroCYST. The screening process starts with the signature of the IC. All patients that fulfill our defined 
54 inclusion criteria, do not fulfill any of the exclusion criteria and provided written informed consent are 
55 considered for enrollment. Those who do not meet all the inclusion or do meet one or more of the 
56 exclusion criteria will be considered as screening failures and will not be enrolled in the study. For 
57 reducing the risk of a sampling bias, we propose the following approach: A stratification per study center 
58 of at least 40% of enrolled patients with eGFR greater or equal than 60 ml/min*1.73m2. 
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3 5.2 Nothing is stated about the fact whether these will be “incident” or “prevalent” patients, 
4 whereas  this would however have a severe impact on the later analysis of the data. 
5 According to our study design the recruited patients will be predominantly prevalent patients. Since 
6 ADPKD is a genetic disorder for which there is no effective treatment available yet, we expect no 
7 difference between incident and prevalent patients with respect to the rate of disease progression. In 
8 
addition, the time after diagnosis will be recorded in the database, which can be used for later analysis 
9 
of data. 
11 
12 6. Line 35, page 11: “To this end an open and transparent ancillary study  policy has been 
13 established” can authors specify where this “transparent” study  policy can be found? 
14 Ancilllary studies will be evaluated by the Steering Committee and decision making is based on 3/4 
15 vote. This ancillary study policy is described in the study protocol that has been added as 
16 supplementary material to the manuscript (S1). 
17 
18 
6.1 Has the study  protocol in full been posted and published? If yes, the place where the reader 
19 
can find this  information should be provided; if no, the current paper should be reformatted to 
21 comply with the STROBE regulations (http://www.strobe-statement.org/) 
22 The study protocol hasn’t been posted or published so far. We have therefore added the study protocol 
23 in the supplement of this manuscript. A reference to this supplementary material has been incorporated 
24 in the revised version of the manuscript (EuroCYST strategy and organization). 
25 
26 7. Who will pay for the MRI and the additional lab costs? 
27 Each center will receive a predefined amount of money per enrolled patient per visit. The amount of 
28 
money paid for the baseline visit, that includes a mandatory MRI, covers the costs for imaging as well 
29 
as additional lab costs. Due to the limited amount of money the second MRI, that should take place at 
31 third year visit, is not mandatory, but highly recommended. 
32 
33 8. Who will own the data? 
34 The center’s individual results of the study shall be owned by the center. Each center will provide copies 
35 of all results (including but not limited to CRF’s) to the study coordination center in Zurich. Owner of the 
36 overall data of the Initiative is the EuroCYST steering committee. This information has been added to 
37 the manuscript (paragraph: Data management and protection) 
38 
39 
8.1 Where will the data physically be stored? 
41 The study data are saved on a separate server at the University Hospital Zurich, where the clinical trial 
42 center, provider of the data management system, is located. Server access is controlled physically and 
43 electronically. A daily backup will be performed. This information has been added to the manuscript 
44 (paragraph: Data management and protection). 
45 
46 8.2 Who has access  to the data? 
47 Each center has defined a number of study members that have access to the data management 
48 system. The access to the system is personal, role specific and secured with a password. Each center 
49 
will have access to its own data. The coordination center Zurich will have access to all data that are 
50 
51 stored in the central data management system. Individual participating centers, as well as third parties, 
52 may ask for datasets by submitting proposals for ancillary studies. 
53 
54 9. Who has funded  this study? This is not clear from the paper 
55 The study is funded by a grant of the European Renal Association – European Dialysis and 
56 Transplantation Association (ERA-EDTA) with 1 Million Euro. We added this information to the 
57 manuscript under EuroCYST strategy and organization.
  
 
